In contrast to the proposed benefit of NGAL in predicting long term outcome in nonproteinuric CKD, baseline NGAL levels may not be a useful biomarker to predict medium-term therapeutic response in proteinuric glomerular diseases with relatively preserved tubulointerstitium. Here, LCN2 is linked to chronic kidney disease.